Vion Pharmaceuticals Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other May 8 Calls Today's Calls

Call Details Vion Pharmaceuticals Earnings Conference Call (Q1 2008) Thu, May 8, 2008, 8:30 am Eastern Listen to the archived event audio About Vion Pharmaceuticals (NasdaqCM:VION) Vion Pharmaceuticals, Inc., a development-stage pharmaceutical company, together with its subsidiaries, develops and commercializes therapeutics for the treatment of cancer. The company’s products in clinical development include Cloretazine, an alkylating agent that is in new phase 3 trial development stage for the treatment of relapsed acute myelogenous leukemia (AML); in phase 2 trial for the treatment of de novo poor-risk AML in previously untreated elderly patients; in phase I investigator-sponsored trial in combination with stem cell transplantation for patients with poor-prognosis hematologic malignancies; and in phase I/II investigator-sponsored trial in combination with temozolomide for the treatment of adult brain tumors. It also conducts a phase 1 clinical trial of an oral formulation of Triapine that is used to prevent the replication of tumor cells. In addition, the company’s products in preclinical development include VNP40541, a cytotoxic compound for hypoxic cells found in cancerous tumors; and TAPET, a drug delivery technology for the treatment of cancer. Further, its other products include MELASYN, a water-soluble, synthetic version of melanin that is used as an ingredient for formulation of skin care products and cosmetics; and elvucitabine, which is in phase II clinical trial for the treatment of human immunodeficiency virus and hepatitis B. Vion Pharmaceuticals has licensing agreements with Yale University related to Cloretazine, Triapine, MELASYN, and elvucitabine products; and with Austrian Inventors and Austria Wirtschaftsservice Gesellschaft m.b.H. for the development of hydrazones. The company was founded in 1992. It was formerly known as OncoRx, Inc. and changed its name to Vion Pharmaceuticals, Inc. in 1996. Vion Pharmaceuticals is based in New Haven, Connecticut. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings